Risk factors for cancer in patients with primary biliary cholangitis and autoimmune hepatitis and primary biliary cholangitis overlap syndrome Michelle Harriz Braga; Guilherme Grossi Lopes Cançado; Paulo Lisboa Bittencourt; Cláudia Alves Couto; Laura Vilar Guedes; André Mourão Costa Lima; Maria Lucia Gomes Ferraz; Cristiane Alves Villela-Nogueira; Mateus Jorge Nardelli; Luciana Costa Faria; Nathalia Mota de Faria Gomes; Elze Maria Gomes Oliveira; Vivian Rotman; Maria Beatriz Oliveira; Simone Muniz Carvalho Fernandes da Cunha; Marlone Cunha-Silva; Liliana Sampaio Costa Mendes; Claudia Alexandra Pontes Ivantes; Liana Codes; Valéria Ferreira de Almeida e Borges; Fabio Heleno de Lima Pace; Mario Guimarães Pessoa; Izabelle Venturini Signorelli; Gabriela Perdomo Coral; João Galizzi Filho; Aline Lopes Chagas; Debora Raquel Benedita Terrabuio; Eduardo Luiz Rachid Cançado;

Camrelizumab combined with transcatheter arterial chemoembolization and sorafenib or lenvatinib for unresectable hepatocellular carcinoma: A multicenter, retrospective study Xiumei Jiang; Pan Wang; Ke Su; Han Li; Hao Chi; Fei Wang; Yu Liu; Ke Xu;

Surveillance and management of hepatocellular carcinoma after treatment of hepatitis C with direct-acting antiviral drugs Caiyun Yang; Fengxiang Lv; Jiaqi Yang; Dawei Ding; Lina Cui; Ying Han;